Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK557296 in Premature Ejaculation
NCT01021553Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of epelsiban in premature ejaculation (PE) (3 arms), sponsored by GSK. Primary endpoint: Intravaginal Ejaculatory Latency Time at 8 weeks. Started Dec 2009; status: completed.
02
Drugs
epelsiban
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on NCT01021553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01021553.